Dr Reddys Laboratories Ltd Quarterly Results
Q4 FY25-26 Results Summary
Revenue
The revenue stands at ₹7,546.40 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 13.79 per cent from ₹8,753.40 crore. This corresponds to a year-on-year *(YoY) decline of 11.51 per cent.
Operating Profit
Operating Profit stands at ₹640.00 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 66.57 per cent from ₹1,914.50 crore. This corresponds to a year-on-year *(YoY) decline of 69.15 per cent.
PBDT
PBDT stands at ₹756.80 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 63.34 per cent from ₹2,064.20 crore. This corresponds to a year-on-year *(YoY) decline of 69.23 per cent.
Profit Before Tax
Profit Before Tax stands at ₹199.70 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 87.06 per cent from ₹1,543.20 crore. This corresponds to a year-on-year *(YoY) decline of 90.04 per cent.
Net Profit
Net Profit stands at ₹221.30 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 81.40 per cent from ₹1,189.60 crore. This represents a 86.05 per cent year-on-year *(YoY) decline for the same year.
- YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.
Dr Reddys Laboratories Ltd News
Dr Reddys Laboratories Ltd Earnings
- YOY
- QOQ
Dr Reddys Laboratories Ltd Earning Charts
Revenue from Operations
in ₹ cr
EBITDA
in ₹ cr
Profit before Tax
in ₹ cr
Net Profit
in ₹ cr
Dr Reddys Laboratories Ltd Research Reports
Dr Reddys Laboratories Ltd Financial Reports
Dr Reddys Laboratories Ltd Stock Prices Compare with Peers
| Company | 1 Day | 1 Week | 1 month | 3 month | 6 month | 1 Year |
|---|---|---|---|---|---|---|
| Dr Reddy's Labs | 0.66% | 2.57% | -2.38% | -0.12% | 2.47% | -3.02% |
| Torrent Pharma. | 1.61% | 1.60% | -1.26% | 5.06% | 18.39% | 39.94% |
| Cipla | 1.39% | 5.84% | 1.52% | 15.36% | -4.65% | -4.97% |
| Zydus Lifesci. | 2.56% | 3.52% | 3.64% | 23.07% | 22.01% | 14.07% |
| Lupin | 0.49% | 1.25% | 2.99% | 0.39% | 11.53% | 21.77% |
| Mankind Pharma | -0.29% | 5.19% | 2.97% | 25.22% | 15.40% | 9.56% |
| Aurobindo Pharma | 2.28% | 6.03% | 5.27% | 17.01% | 26.88% | 36.60% |
Company Info
Company Information
Co-Chairman & Managing Director : G V Prasad
Executive Chairman : K Satish Reddy
Independent Director : Shikha Sanjaya Sharma
Independent Director : Leo Puri
Independent Director : K P Krishnan
Independent Director : Pennv Wan
Company Sec. & Compli. Officer : K Randhir Singh
Independent Director : Arun M. Kumar
Independent Director : Claudio Albrecht
Independent Director : Sanjiv Mehta
Independent Director : Alpna Seth